| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Willie Earley, Hua Guo, David Daniel, Henry Nasrallah, Suresh Durgam, Yan Zhong, Mehul Patel, Ágota Barabássy, Balázs Szatmári, György Német. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. Schizophrenia research. vol 204. 2020-03-04. PMID:30172595. |
in patients with acute schizophrenia and moderate/severe negative symptoms, cariprazine was associated with significantly greater improvement in negative symptoms compared with placebo and aripiprazole, warranting further exploration of the efficacy of cariprazine on negative symptoms. |
2020-03-04 |
2023-08-13 |
Not clear |
| Davide Martino, Vikram Karnik, Sydney Osland, Thomas R E Barnes, Tamara M Pringshei. Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2020-02-25. PMID:29758999. |
we conducted meta-analyses of randomised controlled trials included in the cochrane database of systematic reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with sgas (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, l-sulpiride, and ziprasidone) approved in canada and the uk, comparing them with haloperidol and chlorpromazine. |
2020-02-25 |
2023-08-13 |
Not clear |
| Alexandre Lachance, Olivier Corbeil, Stéphanie Corbeil, Guillaume Chalifour, Ann-Sophie Breault, Marc-André Roy, Marie-France Demer. Case Reports of Aripiprazole and Problematic Gambling in Schizophrenia: A Critical Review of the Evidence. Journal of clinical psychopharmacology. vol 39. issue 4. 2020-02-18. PMID:31206391. |
case reports of aripiprazole and problematic gambling in schizophrenia: a critical review of the evidence. |
2020-02-18 |
2023-08-13 |
Not clear |
| N N Ivanets, M A Vinnikova, E V Ezhkova, M S Titkov, R A Bulatov. [Aripiprazole and quetiapine in the treatment of patients with 'dual diagnosis' of schizophrenia and drug addiction]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 119. issue 9. 2020-02-03. PMID:31626219. |
[aripiprazole and quetiapine in the treatment of patients with 'dual diagnosis' of schizophrenia and drug addiction]. |
2020-02-03 |
2023-08-13 |
Not clear |
| N N Ivanets, M A Vinnikova, E V Ezhkova, M S Titkov, R A Bulatov. [Aripiprazole and quetiapine in the treatment of patients with 'dual diagnosis' of schizophrenia and drug addiction]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 119. issue 9. 2020-02-03. PMID:31626219. |
the randomized comparative study of aripiprazole and quetiapine in the treatment of patients with 'dual diagnosis' of schizophrenia and drug addiction. |
2020-02-03 |
2023-08-13 |
Not clear |
| Mohammad Ebrahimzadeh, Mostafa El Mansari, Pierre Blie. Synergistic effect of aripiprazole and escitalopram in increasing serotonin but not norepinephrine neurotransmission in the rat hippocampus. Neuropharmacology. vol 146. 2020-01-23. PMID:30414871. |
in addition to schizophrenia and bipolar disorder, aripiprazole is approved as an adjunct for major depressive disorder (mdd). |
2020-01-23 |
2023-08-13 |
rat |
| Sally Mustafa, Joanna Bougie, Maia Miguelez, Guerline Clerzius, Emmanouil Rampakakis, Jean Proulx, Ashok Mall. Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study. BMC psychiatry. vol 19. issue 1. 2020-01-21. PMID:30991969. |
real-life assessment of aripiprazole monthly (abilify maintena) in schizophrenia: a canadian naturalistic non-interventional prospective cohort study. |
2020-01-21 |
2023-08-13 |
Not clear |
| Sally Mustafa, Joanna Bougie, Maia Miguelez, Guerline Clerzius, Emmanouil Rampakakis, Jean Proulx, Ashok Mall. Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study. BMC psychiatry. vol 19. issue 1. 2020-01-21. PMID:30991969. |
with previously established efficacy of aripiprazole once-monthly injectable formulation (aom) in pre-registration randomized controlled trials, the current study was designed to evaluate its effectiveness in patients treated for schizophrenia in regular clinical settings in canada. |
2020-01-21 |
2023-08-13 |
Not clear |
| Miko Taniguchi, Masakazu Hatano, Hiroyuki Kamei, Risa Inagaki, Shigeki Yamad. Factors That Affect Continuation of Antipsychotic Long-Acting Injections. Biological & pharmaceutical bulletin. vol 42. issue 7. 2019-12-19. PMID:31257286. |
the study population included patients with schizophrenia who were undergoing lai treatment involving risperidone, paliperidone, or aripiprazole at fujita health university hospital between october 2009 and june 2017. |
2019-12-19 |
2023-08-13 |
Not clear |
| Mallik Greene, Chakkarin Burudpakdee, Arpamas Seetasith, Michael Behling, Holly Kras. Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers. Current medical research and opinion. vol 35. issue 1. 2019-12-02. PMID:30322282. |
patient support programs, such as the assure program for long-acting injectable aripiprazole, are designed to help support access to medications, including long-acting injectable (lai) antipsychotics for patients with schizophrenia. |
2019-12-02 |
2023-08-13 |
Not clear |
| L Samalin, T Charpeaud, P-M Llorc. [Aripiprazole long-acting for the maintenance treatment of schizophrenia.] L'Encephale. vol 40. issue 6. 2019-11-20. PMID:25453734. |
[aripiprazole long-acting for the maintenance treatment of schizophrenia.] |
2019-11-20 |
2023-08-13 |
Not clear |
| L Samalin, T Charpeaud, P-M Llorc. [Aripiprazole long-acting for the maintenance treatment of schizophrenia.] L'Encephale. vol 40. issue 6. 2019-11-20. PMID:25453734. |
as mentioned in various professional recommendations, long-acting injectable antipsychotics, so long-acting injectable aripiprazole, are one of the major strategies of the maintenance treatment for patients with schizophrenia. |
2019-11-20 |
2023-08-13 |
Not clear |
| Giovanni Amodeo, Chiara Candiracci, Ilaria Capecci, Sergio De Filippis, Sonia Giuliani, Giorgio Guerani, Carmine Tomasetti, Vincenzo Villari, Andrea Fagiolin. Starting aripiprazole long-acting-once-a-month early in treatment: why, how and for whom? Expert consensus and practical recommendations by a panel of Italian clinicians. Expert opinion on pharmacotherapy. vol 17. issue 16. 2019-11-20. PMID:27690670. |
aripiprazole long acting once-monthly (aom) is approved for the treatment of schizophrenia in adults. |
2019-11-20 |
2023-08-13 |
Not clear |
| . Correction: Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study. PloS one. vol 12. issue 11. 2019-11-20. PMID:29155881. |
correction: relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: a post-hoc analysis of the qualify study. |
2019-11-20 |
2023-08-13 |
Not clear |
| Mi Seon Kim, Byong Chul Yoo, Woo Seok Yang, Sang Yun Han, Deok Jeong, Jun Min Song, Kyung Hee Kim, Adithan Aravinthan, Ji Hye Kim, Jong-Hoon Kim, Seung Cheol Kim, Jae Youl Ch. Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action. Oncotarget. vol 9. issue 5. 2019-11-20. PMID:29464048. |
aripiprazole (arp) is an atypical anti-psychotic drug widely used to treat schizophrenia and bipolar disorder. |
2019-11-20 |
2023-08-13 |
mouse |
| Keiko Kanno-Nozaki, Itaru Miura, Haruka Kaneko, Sho Horikoshi, Takafumi Ota, Michinari Nozaki, Hiroki Ejiri, Mitsuharu Yahiro, Kenya Watanabe, Mizuki Hino, Hirooki Yab. Influences of the T102C polymorphism in the 5-HT2A receptor gene on the five-factor model of Positive and Negative Syndrome Scale and treatment response to aripiprazole in patients with acute schizophrenia. Psychiatry research. vol 265. 2019-11-20. PMID:29763842. |
influences of the t102c polymorphism in the 5-ht2a receptor gene on the five-factor model of positive and negative syndrome scale and treatment response to aripiprazole in patients with acute schizophrenia. |
2019-11-20 |
2023-08-13 |
Not clear |
| Massimiliano Buoli, Chiara Rovera, Cecilia Maria Esposito, Silvia Grassi, Wiepke Cahn, A Carlo Altamur. THE USE OF LONG-ACTING ANTIPSYCHOTICS FOR THE MANAGEMENT OF AGGRESSIVENESS IN SCHIZOPHRENIA: A CLINICAL OVERVIEW. Clinical schizophrenia & related psychoses. 2019-11-20. PMID:29944415. |
aripiprazole depot appears to be promising for the management of aggressive behaviour of subjects with schizophrenia, however data about its efficacy in the long-term are absent and lack of evidence prevents the recommendation of this compound for the treatment of aggressiveness in subjects affected by schizophrenia. |
2019-11-20 |
2023-08-13 |
human |
| Massimiliano Buoli, Chiara Rovera, Cecilia Maria Esposito, Silvia Grassi, Wiepke Cahn, A Carlo Altamur. THE USE OF LONG-ACTING ANTIPSYCHOTICS FOR THE MANAGEMENT OF AGGRESSIVENESS IN SCHIZOPHRENIA: A CLINICAL OVERVIEW. Clinical schizophrenia & related psychoses. 2019-11-20. PMID:29944415. |
with oral clozapine and aripiprazole depot) are needed to assess the real clinical advantage of the use of depot antipsychotic versus oral alternatives for the prevention of violent behaviour in schizophrenia. |
2019-11-20 |
2023-08-13 |
human |
| Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. Human psychopharmacology. vol 33. issue 4. 2019-11-20. PMID:29992643. |
predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. |
2019-11-20 |
2023-08-13 |
Not clear |
| Naoki Hashimoto, Atsuhito Toyomaki, Tamaki Miyamoto, Akane Miyazaki, Ichiro Kuksum. Olanzapine, blonanserin, and aripiprazole associated with different frontostriatal reward system activation in patients with schizophrenia. Schizophrenia research. vol 197. 2019-11-11. PMID:29223323. |
olanzapine, blonanserin, and aripiprazole associated with different frontostriatal reward system activation in patients with schizophrenia. |
2019-11-11 |
2023-08-13 |
Not clear |